D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
“ThisprojecthasreceivedfundingfromtheEuropeanUnion’sHorizon2020researchandinnovationprogrammeundergrantagreementNo690211”
DeliverableNumber:D4.4,Version1.1
TargetGroupDefinition
Ref. Ares(2016)4900147 - 31/08/2016
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page2of34
ProjectNumber 690211 Acronym CAREGIVERSPRO-MMD
Fulltitle Self-management interventions and mutual assistance community services,helping patients with dementia and caregivers connect with others forevaluation,supportandinspirationtoimprovethecareexperience
Projectcoordinator UniversitatPolitècnicadeCatalunya-BarcelonaTechProf.UlisesCortés,[email protected]
ProjectURL http://www.caregiversprommd-project.eu
Deliverable Number D4.4 Title TargetGroupDefinition-firstversion
Workpackage Number WP7 Title PilotPreparation
Dateofdelivery Contractual Actual
Nature ReportþDemonstratorpOtherp
DisseminationLevel PublicpConsortiump
Keywords
Authors(Partner) DrIsabelleLandrin-Dutot(CHURouen),FrédéricTétard(MDA),
ResponsibleAuthor1 DrIsabelleLandrin-Dutot Email [email protected]
Partner CHU Phone +33232886552
ResponsibleAuthor1 FrédéricTétard Email [email protected]
Partner
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page3of34
Executivesummary:CAREGIVERSPRO-MMDisatoolintegratingabroaderdiagnosticapproach,incorporatingthe“live-in family” caregiver - people with mild cognitive impairment or mild to moderatedementia”dyadandconsideringthisdyadastheunitofcare.
Thisdocumentdescribes the target groups for thepilot study:wewill pilot theoptimisedapplication with 600 dyads to evaluate the clinical and social benefits for PLWD andcaregivers,aswellasfinancialbenefitsforthehealthcaresystem.
This deliverable will also elaborate the strategy of identification/definition of the targetgroups, the channel tomapandengage them, the scenariodefinitionup to the customerprofiling.
ListofAcronyms
Acronym Title
C-MMD CAREGIVERSPRO-MMDplatform
GP GeneralPractitioner
PLWD People living with Mild Cognitive Impairment and with Mild to ModerateNeurocognitiveDisorders.
MCI MildCognitiveImpairment
DSM DiagnosticandStatisticalManualofMentalDisorders
ICT InformationandCommunicationTechnology
CDR ClinicalDementiaRating
MMSE MiniMentalStateExamination
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page4of34
ListofTablesTable1:C-MMDUsersdescription...........................................................................................7
Table2:FirstLevel:generalpopulation...................................................................................8
Table3:Secondlevel:Professionaldementiacarers...............................................................9
Table4:Thirdlevel:medicaldoctors.....................................................................................10
Table5:InclusionandexclusioncriteriaforPLWD................................................................10
Table6:Inclusionandexclusioncriteriaforcaregivers.........................................................11
Table7:Diagnosisprocedures...............................................................................................12
Table8:Selectionprocessforinclusion.................................................................................14
Table9:Barrierstoachieveenrolment.................................................................................15
Table10:proportionofdifferenttypesofcaregivers............................................................16
Table11:Keyfactorsforsuccessfultrialimplementationandcompletion...........................17
Table12:KeyfactorstoimproveenrolmentforPLWD.........................................................21
Table13:EngagementquestionnaireforPLWD....................................................................22
Table14:KeyfactorstoimproveenrolmentforCaregivers.................................................24
Table15:EngagementquestionnaireforCaregivers............................................................24
Table16:Retentionriskmitigationstrategies.......................................................................29
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page5of34
Tableofcontent
1 INTRODUCTION 72 TARGETGROUPDEFINITION 82.1 LEVELOFSCREENINGFORTARGETGROUPS: 8
2.1.1 FIRSTLEVEL:GENERALPOPULATION 82.1.2 SECONDLEVEL:PROFESSIONALDEMENTIACARERSINTHECOMMUNITY 92.1.3 THIRDLEVEL:MEDICALDOCTORS 9
2.2 THEDYAD 102.2.1 PLWD 112.2.2 CAREGIVER 13
2.3 SELECTIONPROCESSFORINCLUSION 143 CLINICALTRIALSINDEMENTIA 153.1 BARRIERSTOACHIEVEENROLMENT 153.2 FACTORSIMPACTINGTRIALCOMPLETION 173.3 HIGHLEVELCHALLENGEMITIGATION 17
4 STRATEGYFORENROLMENT 194.1 IDENTIFYCOMMUNITIES 194.2 BENEFITSOFPARTICIPATION 194.3 RECRUITMENTTOOL 194.4 ON-LINESTRATEGYTOSUPPORTENROLMENT 20
5 STRATEGYFORENGAGEMENT 215.1 STRATEGYFORPLWD 21
5.1.1 IMPROVINGCONSENT 215.1.2 COMMUNICATION 225.1.3 ENGAGEMENT 225.1.4 BUILDCONFIDENCEANDTRUSTFORPLWDS 23
5.2 STRATEGYFORCAREGIVER 245.2.1 IMPROVINGCONSENT 245.2.2 COMMUNICATION 245.2.3 ENGAGEMENT 245.2.4 BUILDCONFIDENCEANDTRUSTFORCAREGIVERS 25
5.3 STRATEGYFORMEDICALDOCTORS 265.4 STRATEGYFORSOCIALPROFESSIONALS 27
6 STRATEGYFORRETENTION 296.1 CATEGORIZINGPARTICIPANTS 296.2 POSSIBLERISKMITIGATIONSTRATEGIES 29
7 ANNEXES 317.1 ANNEX1:DSM-IVCRITERIAAPA1994 317.2 ANNEX2:MCI-ALBERT-PETERSEN2011 317.3 ANNEX3:RESEARCHATTITUDEQUESTIONNAIRE-7ITEM 31
8 REFERENCES 33
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page6of34
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page7of34
1 INTRODUCTIONAswithmostchronicdiseases,acollaborativepartnershipamongPLWD,caregiver (formaland/orinformal),healthprofessionals(clinicians(GPsandspecialists),nurses,psychologists,pharmacists,etc.)andsocialprofessionals(socialworkers)isneededinordertoachievethehighest quality andefficacy in assessment, treatment and support. CAREGIVERSPRO-MMD(C-MMD) platform is a new device in Information and Communication Technology (ICT)developed for the support and assistance of dyads of patients living with neurocognitivedisordersandtheircaregivers.
The C-MMD platform provides support for interactions between the following platformusers.
Table1:C-MMDUsersdescription
Users Description
PLWDPeoplelivingwithMildCognitiveImpairmentandwithMildtoModerateNeurocognitiveDisorders.
CaregiversPeople providing support and assistance to the PLWD, with or without aprofessionaland formalbackground (e.g. informalor formalcaregiver).Thosearefamilymembers,neighbours,friendsaswellaspaidassistant.
Dyad
IntheframeworkofC-MMDproject,PLWDandtheircaregiversrepresentthemainpoint of care; their interaction with the platform is also determined by therelationshipswithinthedyadandnamelytheseverityofsymptomsandconditionsofbothmembers.
HealthProfessionals
People with healthcare background,managing the health plan of the dyad; theycombineandmanagehealthdataforclinicalassessment,diagnosisandtreatmentplans;
SocialProfessionals
PeoplewithSocialbackground,managingthesocialsupportofthedyad;theydealwith the social component of the intervention, in order to improve outcomes indyad’slivesandrelationships,withspecialfocusontheirsocialstatus.
Toevaluate thebenefits of CAREGIVERSPRO-MMDplatformuse, amulticentrepilot studywillbeconductedin4countries(France,GreatBritain,ItalyandSpain)during18months.
For thispilot study, it isnecessary todefine the targetgroupsconcerned inorder tohavereliableresultsandtominimizedropoutrates.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page8of34
2 TARGETGROUPDEFINITIONThepilotstudyconsistsinevaluatingthebenefitsofCAREGIVERSPRO-MMDplatformuseforthesupportandassistanceofdyadslivingwithneurocognitivediseases.Thepilotstudywillenrol dyads involved in dementia care. In this context, the definition of target groupdescribesgroupsofpeoplewithcommoncharacteristics,andsimilarlifesituations.
Thedefinitionoftargetgroupisinfluencedbymanyfactorslistedbelow:
- ThedyadcomposedofacaregiverandPLWD- TheabilitytouseanICTdevice- Theabilitytoparticipateandcompleteapilotstudy
Therearedifferent levelsof screening. Foreach levelof screening, target groupsmustbedefined. It has been decided to define different levels depending on the way dyads arerecruited.
Theselevelsofscreeningare:
- Level1:screeninginthegeneralpopulation
- Level2:screeningbyprofessionalcaregiversofdementia incommunity(publicsectorsandvoluntaryorganizations,etc.)
- Level3:screeningbymedicaldoctors
Manyquestionsareraisedbythisstudy
- Whoselectsdyads- Wherethedyadsarerecruited(orselected):inthegeneralpopulation,memory
clinics,daycarehospital,generalpractitioners,etc.- How to select dyads involved in the project: medical screening, media,
newspapers,andInternet.
2.1 Levelofscreeningfortargetgroups:
Inordertorecruit600dyadswithinafewweeks,itisnecessarytodecidedifferentlevelsofscreening.
2.1.1 Firstlevel:generalpopulation
Thegeneralpopulationrepresentsthefirst level.Manydyads,whichfacethedisease,maywanttoparticipateinaresearchprotocol.Thisfirstlevelisagenerallevelofscreeningandamedicalevaluationisneededtodecideifthedyadshouldbeincludedinthestudy.
Table2:FirstLevel:generalpopulation
TargetGroup FirstLevel:GeneralPopulation
DyadComposed of a person living with cognitive problems, eventually with a knowndiagnosisofdementiaorMCIandacaregiver (relative, friend,professional)whoprovidesabroadrangeofassistance
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page9of34
CaregiverA person who provides support and assistance and accepts to participate andcompletethestudy.He/shehasbasicknowledgeofICT
Basicknowledgeisdefinedashavingminimumknowledgeofusingacomputerorlaptoportablet:tobeabletologon,tosurftheinternet(i.e.:connectingtoasearchengineanddoabasicsearch),tosendarequestoranemail.
Oneofthesuccessesoftimelyenrolmentisawarenessofthestudy.Adyadcannotchoosetoparticipateifthisdyadisnotawareofthestudy.
Forthisfirstlevel,wesuggestdifferentwaysforrecruiting.Informationandbenefitsoftheprojectcouldbecommunicatedinthelocalpress,media(TV),advertising,Internetviasocialmedia (twitter, Facebook,etc.), voluntaryassociations (Alzheimer’sdisease, for caregivers,etc.).
Thisisthefirstlevelofscreening.Contactshouldbemadewiththeteampilotingthestudy.
2.1.2 Secondlevel:professionaldementiacarersinthecommunity
AsecondleveltoscreendyadsisrepresentedbyprofessionalswhotakecareofPLWDandtheircaregivers:publicandprivatecaresectorsandvoluntaryorganizations.
This group is represented by social workers, nurses, psychologists, professional helpers,volunteers,etc.Theycanrelayinformationontheprotocolresearch.
Forthissecondlevel,wecansuggestdifferentwaysfordissemination:specific informationdedicated to local services, localpress,advertising, Internet (email),voluntaryassociations(onAlzheimer’sdisease,forcaregivers,etc.),
Table3:Secondlevel:Professionaldementiacarers
TargetGroup Secondlevel:professionaldementiacarers
DyadPeople livingwith cognitive problems,with a known diagnosis of dementia orMCI and who have a caregiver (relative, friend, professional) who provides abroadrangeofassistance
Caregiver
People providing real support and assistance to the PLWD, with or without aprofessionalandformalbackground(e.g.informalorformalcaregiver).He/sheisin goodhealth andaccepts toparticipate and complete the study.He/shehasbasicknowledgeofICTandinternetaccess.
Afterthisscreening,personswhomeetthecriteriashouldbereferredtotheteampilotingthestudy.
2.1.3 Thirdlevel:Medicaldoctors
Medical doctors represent the third level. These professionals are general practitioners,neurologists, psychiatrists, geriatricians, etc. Some of thesemedical doctors may work inmemoryclinics,hospitalday-care,etc.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page10of34
ThesemedicaldoctorswillreceivespecificinformationontheresearchprotocolviaInternetorbypost,orinamedicalmeeting.
Ascreeningofdyads,whichare followed inmemoryclinics,hospitalday-care,etc., shouldbe done. The pilot teamwill contact thosemeeting the criteria in order to propose theirparticipationinthestudy.
Table4:Thirdlevel:medicaldoctors
TargetGroup Thirdlevel:medicaldoctors
PLWD
People living, with a known and established diagnosis of mild to moderatedementiaorMCIandwhofulfiltheinclusionandexclusioncriteriaandwhohavea caregiver (relative, friend, professional) who provides a broad range ofassistance.Thecaregivermustfulfiltheinclusionandexclusioncriteria.
Caregiver
People providing real support and assistance to the PLWD, with or without aprofessionaland formalbackground (e.g. informalor formalcaregiver).He/shefulfils the inclusion and exclusion criteria and accepts to participate andcompletethestudy.He/shehasbasicknowledgeofICTandinternetaccess.
Basicknowledgerequiredwillbedefinedashavingminimumknowledgeinusingacomputerorlaptoportablet:tobeabletologon,tosurfinternet(i.e.:connectingtoasearchengineanddoabasicsearch),tosendarequestoranemail.
2.2 TheDyad
Thedyad iscomposedofacaregiverandaPLWDwhoareclosely linkedregardingdiseasecare.Eachmemberof thedyadmustbe selectedaccording to the inclusionandexclusioncriteriadefinedinthedeliverableD4.1entitled“PilotOperationManual”.
These inclusion and exclusion criteria are listed in Table 1 for PLWD and Table 2 forCaregivers.
Table5:InclusionandexclusioncriteriaforPLWD
InclusioncriteriaforPLWD
● People,aged50andover,livinginthecommunity,whoareabletogiveinformedconsent(orthelegaltutor).
● Diagnosedwithmildcognitiveimpairment(MCI)accordingtoPetersencriteria[AlbertMSet al, 2011] (1) or mild to moderate dementia diagnosed according on DSM-IV criteria(DiagnosticandStatisticalManual,4thedition)[AmericanPsychiatricAssociation,1994](2).
● HavingaClinicalDementiaRating(CDR)of0.5forMCI,1-2formildtomoderatedementia.● Having aMini-Mental Exam score (MMSE) [Folstein et al. 1975] (3) between 30 and 25
(inclusive)forMCI,andbetween24and10(inclusive)fordementia.● Havingaprimarycaregiver,familiar(ornot),informal(ornot)identifiedandalsoincluded
inthestudy.● Willingness to use Information Technology and Communications (ICT) according to the
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page11of34
investigatorcriteria.
Exclusioncriteria
Terminalorsevereillnesswithsurvivalprognosislessthan18months.Havingdelusions,hallucinations,behaviouraldisturbances,thatmayinterferewiththeuseofInformationandCommunicationsTechnology(ICT)tools.Relevant sensory problems (visual or hearing impairment) or motor disability (such asparalysis of upper limb or disabling arthritis or disabling tremor, etc.) evaluated by theinvestigator that would interfere with the use of Information and CommunicationsTechnology(ICT)tools.Notspeakingthelanguageofthecountrywherethepilotisbeingconducted.
Table6:Inclusionandexclusioncriteriaforcaregivers
InclusioncriteriaforCaregivers
People, aged 18 years and over, with no diagnosis or no evidence of mild cognitiveimpairment or mild to moderate dementia (according DSM-IV criteria) [AmericanPsychiatricAssociation,1994],whoareabletogiveinformedconsentandwithanintentiontocompletethestudy.Primary caregivers, informal (or not), familiar (or not) of person with mild cognitiveImpairmentormildtomoderatedementia.PeoplewithInternetaccessandbasicknowledgeandskillsinmanaginginternetandsocialnetworks,orkeentolearn,accordingtotheinvestigatorcriteria.Having a Geriatric Depression Scale (GDS-Yesavage - 15 items) score less than 11 at thetimeofentryintothetrialindicatingnoseveredepressivesymptoms.Havingnospecificconditions(evaluatedbytheinvestigator)reducingtheirphysicalabilitiesbelow thenorm for their age thatwould limit or impair CAREGIVERSPRO-MMDplatformuse.WillingnesstouseInformationTechnologyandCommunications(ICT)tools.
ExclusioncriteriaforCaregivers
Terminalorsevereillnesswithsurvivalprognosislessthan18months.Relevant sensory problems (visual or hearing impairment) or motor disability (such asparalysis of upper limb or disabling arthritis or disabling tremor, etc.) evaluated by theinvestigator that would interfere with the use of Information and CommunicationsTechnology(ICT)tools.Notspeakingthelanguageofthecountrywherethepilotisbeingconducted.
2.2.1 PLWD2.2.1.1 Age
ThestudyaimstorecruitPLWDaged>50years.Therewillbetwodifferentgroups.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page12of34
First,theyoungerpatientswillbemorelikelytohaveaspouseascaregiver,livingwiththem;mostofthemwillhaveaprofessionalactivity.YoungerpatientswillbemorelikelytohaveknowledgeofICTandbewillingtoparticipateinthetrial.
Thesecondgroupwillbecomposedofelderlypatients.Probably,thecaregiverswillmostlybe their children.We cannot expect to include elderly spouses in a study on ICT as theirknowledgeispoorandweshouldfocusonchildrenascaregivers.
2.2.1.2 DiagnosisproceduresOneofthekeypointsoftherecruitmentinthepilotstudyistohavePLWDwithadiagnosisof the disease. Only patients with Mild Cognitive Impairment and patients with mild tomoderatedementiawillparticipateinthestudy.Table7:Diagnosisprocedures
AdiagnosisofdementiaaccordingtoDSM-IVcriteria
A diagnosis of dementia, according to DSM-IV criteria (Diagnostic andStatistical Manual, 4th edition) [American Psychiatric Association,1994](2) should have been done according to the clinical practicebefore inclusion. This is necessary in order to eliminate differentialdiagnosisthatcouldleadtodrop-out(seeannex1).
The diagnosis must have been done by a medical doctor trained(neurologist,geriatrician,psychiatrist,etc.).
The level of severity of the disease must be determined by medicaldoctors or psychologists using CDR and MMSE done by a trainedprofessional.
ADiagnosisofmildcognitiveimpairment(MCI)accordingtoPetersencriteria
ADiagnosisofmildcognitiveimpairment(MCI)accordingtoPetersencriteria[AlbertMSetal,2011(1)](seeannex2)shouldhavebedoneaccordingtotheclinicalpracticebeforeinclusion.
Thediagnosismusthavebeendonebyamedicaldoctortrainedinthispractice(neurologist,geriatrician,psychiatrist,etc.).
Remark:Nobiomarkerstudywillbenecessaryforthisstudy.2.2.1.3 Aetiologyofdementia
Forthepilotstudy,aetiologyofdementiaisnotnecessaryasinclusioncriteria.However,inordertohavehomogeneousgroupsithasbeendecidedtoavoidincludingPLWDwithseverebehaviouraldisturbanceordelusionsorhallucinationsevaluatedbyamedicaldoctorafterquestioningthecaregiver.
2.2.1.4 ICTknowledge
NoICTknowledgeisrequiredforPLWDbutaninterestorsomeknowledgeinICTwouldbeappreciated.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page13of34
Most younger PLWD may have already used a computer, smartphone, software, andInternet.
2.2.2 Caregiver
As for the PLWD, it is important to determine the target group for caregivers. There aremanycriteria.
First,thecaregiverisdefinedasanyrelative,partnerorfriendwhohassignificantpersonalrelationshipwiththePLWD,andprovidesabroadrangeofassistance.He/shemaylivewithorseparately fromthepersonreceivingthecare.Thecaregiverwillbethemainreferenceforrecruitmentandthestudy.
The target group is peoplewhomeet the inclusion and exclusion criteria andwho acceptparticipatingandcompletingthepilotstudy.Twomaininclusioncriteriamustbetakenintoaccount:absenceofseveredepressionandabsenceofsevereillnessthatwouldlimittheuseofICT.Thiswillbedeemedbytheteampilotingthestudy.
2.2.2.1 ICTknowledge
Asthecaregiverwillbethemaincontributorontheplatform,itisnecessarythathe/shehassufficientknowledgeonICT.Onlybasicknowledgeisrequiredastheplatformisdevelopedwithsimpleandeasydesign.
Basic knowledge will be defined as having minimum knowledge in using a computer orlaptoportablet.Caregiversshouldbeableto:
§ Switch-onandswitch-offacomputer§ Loginandlogoutofaplatform§ Surf internet (i.e.: connecting to a search engine and performing a basic search
action),§ Sendarequesttoanadministratororsendanemail.
2.2.2.2 WillingnesstouseICT
Inorder toparticipate and complete the study, it is important that the caregiverdeclareshis/herwillingnesstousetheplatformandcompletethestudy.
Ahighlevelofdropouthasbeenobservedinpreviousstudiesbutthereisnoreliablescaletoevaluatethewillingnesstocompleteastudy.
TheRAQ7item-scale(ResearchAttitudeQuestionnaire)isusedtoassessthewillingnessofpatients to participate in a study. This scale is not validated for testing an ICT device indementia(4)andnocut-offisdefined.Thisscalemaybeausefultooltohelppilotteamstoselectdyadswhenadoubtispresent.
Thewillingness touse ICT and tobe activeon theplatformwill beevaluatedby thepilotteam.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page14of34
2.3 SelectionprocessforinclusionTheprocesstoselectdyadsinthestudyisdetailedintable8.
Table8:Selectionprocessforinclusion
Steps Check/Action Result
Step1First-second level: Dyad meetingcriteria and willingness toparticipatetoanICTstudy.
Contactwiththepilotteam(email,phone,etc.)
Step2 MedicalappointmentPerson with a diagnosis of MCI or mild tomoderatedementia(PLWD)confirmed
Step3
Did the patient and the caregivergive informed consent afterreceiving information on the studyanddotheyhaveICTabilities?
Dyadcompleted
Step4Evaluation of the severity of thedisease (CDR, MMSE) by medicalteamorpsychologist
The level of severity of disease is defined,inclusionandexclusioncriteriaareverified
Step5
Verification of inclusion andexclusion criteria for caregiverincluding:
§ Does the caregiver have ICTknowledge?
§ Does the caregiver have thewillingness to complete thestudy?
Inclusioninthestudyifalltheseconditionsarepresent
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page15of34
3 CLINICALTRIALSINDEMENTIADifficultiesinrecruitmentforstudyinAlzheimer’sdiseasearefrequentandsomestudiesfailtoenrolintime.Thetimetoenrol600dyads(200inSpain,200inItaly,100inFrance,100inGreatBritain)isshortanditisnecessarytodefinebeforethestudywhatkindofdyadcouldbepreselectedbeforebeingenrolled.
3.1 Barrierstoachieveenrolment
Indementia, researchers facemultiple challenges inorder toachieveenrolment in clinicaltrialswhereasresearchersunderstandtheneedtodeveloptrials.Onlyonethirdof24multi-sitetrialswereabletoenrolvolunteerswithinoneyearinphaseIIorIIIstudies(5).
Thebarriersaremultiple.
Table9:Barrierstoachieveenrolment
Barriers Description
AwarenessoftrialsThosewhoarenotawareoftrialscannotparticipate.Manyindividualsaffectedbydementiadonotknowtheycanparticipateinclinicaltrialsorwheretofindinformationonstudiesintheirarea.
Physicianchallenges
Likepeoplelivingwithdementiaandtheirfamilies,lowphysicianawarenessofdementiaclinicaltrialsandotherstudiesisasignificantchallengetoenrolment.
ThediseaseDementiaischaracterizedbydifficultiesincomprehensionthatmayimpactinformedconsentprocess.Patientsmaydenytheircognitiveimpairment.
Coexistingconditions
Indementiaclinical trialsandotherstudies,Alzheimer’scancomplicatethemanagement of other comorbid health conditions and many people withAlzheimer have one or more of them. High frequency of other medicalproblems thatmaybeexclusioncriteria suchasmedications.Patientsmustbestablebeforeinclusion.
InformedconsentDifficultiestoobtaininformedconsentforpeoplewhoarenotawareoftheirdisease and risk that patient decline proposal even if a legally authorizedrepresentativeagrees.
Culturalandlinguisticdifferences
Having understood oral and written information before signing informedconsent is necessary.An evaluationof clinical practices at 36 centres in 15Europeancountriesrevealedlanguagebarriersandeducationlevelsaffectedadequate cognitive assessment and delivery of services for patients withethnicandminoritybackgrounds.
StudyThe burden due to visits and study pattern is a reason for refusal toparticipate
Previousinclusion A dyad with previous inclusion in a research study is a reason for non-
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page16of34
inresearchstudy inclusion
Requirement toenroltwopeople
Fordementiastudy,aPLWDandacaregiveroraknowledgeableinformantisoftenneeded.(6)
PLWDwhodonothaveacaregiveroraknowledgeableinformantcannotparticipateinthestudy.Theroleofthecaregiverisessentialatinclusion,butalsotomonitorandforfollow-up.ThedecisionofcaregiverstoparticipateornotinthetrialisasimportantasthePLWD’sdecision.However,spousesaremorelikelytoacceptparticipatinginatrial.
Inthefourcountriesparticipatinginthepilotstudy,thepercentageofdifferenttypesofcaregiversislistedintable10.
Table10:proportionofdifferenttypesofcaregivers
Level France UK Italy Spain
Partner 44 42 25 28
Adultchildren 37 46 65 55
Other 13 12 10 17
References [AssociationFrançaisedes
Aidants,2016](7)
LocalMemoryClinicdataof
UniversityofHull
[Spadin,2007](8) [Rivera,2009](9)
[España,2008](10)
Only33%oftrialstudypartnersarenotspouses(11).Spousalcaregiversmayhavegreatermotivationthanchildrencaregiverswhoaremorelikelytobeworkingandhavelesstimetospend in a research study. The barriers for caregivers are multiple such as logistics(transportation, frequency of visits, etc.) but emotional and attitudinal factorsmay play arole(4,12).SomecaregiverscitethedoubtsofbenefitsoftheirparticipationforthePLWDasreasonforrefusingparticipation.Thefearofburnoutisoneofthereasonsofrefusal.
Otherparticipantbarriers:
§ Timeoffwork§ Transportationcosts§ Childcare§ Outof-pocketexpenses§ Notwantingtochangecurrentmedicaltreatment§ Notwantingtochangephysicians§ Mistrustofmedicalresearch
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page17of34
§ Fearofstigmaassociatedwithadisorder/disease,etc.
3.2 Factorsimpactingtrialcompletion
At any time, PLWDs and caregivers canwithdraw their consent to participate in a clinicalstudyasitisstatedinregulatoryandethicalguidelines.
So, good retention begins before enrolment by recruiting participants who are likely tocomplete the study. In medication trials retention rate are about 70%. In ICT studies,dropoutrateishighandmustbetakenintoaccount.
The success of CAREGIVERSPRO-MMD pilot study hinges on ability to recruit and retaindyads.Losingsubjects isathreattothepowertodetectaplatformeffectand,potentially,thismayhaveimpactonthevalidityofthestudy.
InobservationalstudieswithPLWDapercentageofdropoutsupto55%hasbeenreportedat two years of follow-up [13,14]. In studies applying ICT in a similar way toCAREGIVERSPRO-MMD,a40%rateofPLWDdropoutshasbeenrecordedat12months[15].
Withrespecttocaregiverstudieswith interventionsbasedon internetaround28%rateofdropoutshasbeenreportedat6months[16]and33%at12months[17].
Then,afterasearchintheliterature,wewillconsidera60%rateofdropoutsinpeoplewithMild Cognitive Impairment,Mild andModerate Dementia and a 40% rate of dropouts incaregivers.
3.3 Highlevelchallengemitigation
Keyfactorsmustbetakenintoaccountforsuccessfultrialimplementationandcompletion.
Table11:Keyfactorsforsuccessfultrialimplementationandcompletion
Keyfactors Description
Clearcommunication
Informationmustbeclear,adaptedtothepersonconcerned,detailed.Asheetexplainingthetrialisgiventoeachmemberofthedyad.Aperiodofreflectionisproposed.
Informationmustdescribebenefits/risksofthestudy
Dyadsareinformedthattheywillberandomizedincontrolvsplatformgroup.Theconsequencesofthisrandomizationareexplained.
Outcomesmustbeexplained
Datacollectedareexplained
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page18of34
Consistentfollowup
Thescheduleofthetrialmustbeexplainedandpilotteamshavetoverifythedyad’sabilitytoattendappointments.
Datacollectedareexplained
Predefinedrolesandresponsibilities
Theroleandresponsibilitiesofthepilotteamisexplained
Dyadsaccepttheirresponsibilitiesandtheroleofeachmemberofthedyadisexplained
Appropriateplanningandtimelinemanagement
Planningofthetrialisexplainedandappointmentsaremanagedwithdyads’wishes.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page19of34
4 Strategyforenrolment
4.1 IdentifyCommunities
Socialmarketingandcommunity-basedapproachesprovideasolidfoundationfororganizingrecruitmentactivitiesforclinicaltrialswitholderadults.Wewill identifycommunitieswithwhichwewouldliketoengageandestablishlong-termrelationshipsinordertofacilitateourC-MMDstudy.Weconsiderwecouldusequalitativefocusgroupstoassesstheneedsandpreferences of potential participants.Wewill develop plans to share the study results informatsmostusefultothedifferentcommunitiesinvolved,includingparticipants,familiesofparticipants,consumers,andreferringpractitioners.Targetedcommunitiesarethefollowingandalignedwiththesection«2TARGETGROUPDEFINITION»:
• Potentialparticipantsandtheirfamilymembers• Referringphysicians• Community-basedorganizationdirectors• Statementalhealthdirectors• Civicorganizations• Advocacyorganizations• Communitycentres• Healthclinics• Media
4.2 Benefitsofparticipation
Theconsortiumwillworkwithcommunities through focusgroups, interviews,andsurveysto develop a list of benefits (aswell as barriers) for participating in the C-MMD researchstudy. The list of benefits can be communicated to potential participants, and specificbenefitscanbeemphasizedwhenspeakingtodifferentaudiences.
When communicatingwith PLWD, C-MMD clinical teamsmight emphasize that the studyaims to improve the understanding of a disorder and improve their quality of life.Whenspeaking to family members, C-MMD clinical teams will explain that the study will notrequireaPLWDtochangehis/hercurrenttreatmentprogramandwillhelpcaregivertodealwithburn-out.
Aboutbarriersandmitigationmeasures,C-MMDteamswillcreateaFAQsheetaddressingpotentialconcernsinordertoclearupmisconceptions.
4.3 Recruitmenttool
The recruitment tool will be adapted to the target audience (potential participant vs.caregivervs.communityreferralsource)andconductpilottestsandmakesureallstaffwhocommunicateswithpotentialparticipantsreceivepropertraining.
Manyways to communicateon the studywill beused suchas: radioads,newspaperads,flyers, newsletter articles, FAQ sheets, web sites, public service announcements, pressreleases,letterstotheeditor,interviewsonTVorradio,etc.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page20of34
InformationaboutC-MMDclinicaltrialwillbeuploadedtoClinicalTrials.gov.
4.4 On-linestrategytosupportenrolment
New channels of communication will be used to give information on the project such asnetworking.
TheC-MMDteamwillbuildabrandandusevisualcommunicationmaterialstodisseminatearelevantandcoherentmessage.Acommunicationstrategybasedonaclearbrandidentitycanhelptocreateinstantrecognition,provideanassuranceofqualityacrossservices,actasa valuable platform for launching new services, and ensure the delivery of a coherentmessageacrossallmediaofcommunications.ThePilotshavesoughttocreatea‘trustandconfidence’brandthrougharangeofvisualcommunicationaids,suchastaglinesandlogos.Forexample,ashortmemorabletaglinewillhelpcatchcaregiversandPLWD’attentionandpromptthemtotakepartintheinitiative.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page21of34
5 StrategyforengagementTwostagesareimportantduringthepilotstudy:recruitmentandcompletionofthestudybythewholedyad.
Thefirststepistodevelopawarenessofthetrial.Thosewhoarenotawareoftrialscannotparticipate.
Positive PLWD, caregiver, health and social professional engagement is crucial to achievebusinessresultsandthecompletionoftrials.
5.1 StrategyforPLWD
5.1.1 Improvingconsent
For many patients, obtaining informed consent can be a barrier. In order to improveenrolment in the study, inclusion and exclusion criteria are non-restricting in this study.There is no barrier depending on disease (except for terminal illnesses), medications oraetiologyofdementia.
Oneofthedifficultiesisrepresentedbythefactthatpeoplearenotawareoftheirdiseaseor deny their disease or have comprehension impairment. The risk is that a patientmaydecline study inclusioneven if a legally authorized representativeagrees. Thenecessityofclearcommunicationanddemonstrationofthepositiveaspectsoftheirparticipationisakeypoint.
Toimproveenrolmentinstudy,PLWDaremorelikelytoparticipateif:
Table12:KeyfactorstoimproveenrolmentforPLWD
Keyfactors Description
Clearcommunication
§ Theyreceiveclearinformationaboutthetrial.Thisinformationmustbeadaptedtotheleveloftheirdisease(abrochurewithquestionsandanswers-FAQ-willbegiventoPLWD),
§ ExpectedoutcomesforPLWDwillbediscussed,§ DirectindividualbenefitsoftheuseoftheCAREGIVERSPRO-MMD
platformisdiscussedwithPLWDandcaregiver.Directreturnoninvestmentisclearlyexplainedwithpatientandtheircaregivers,
§ Theyareclearlyinformedofethicalproceduresanddataprotection§ Adverseeventsarescarcecomparedtoadrugtrial.Thiswillbe
explainedtothePLWDandcaregiver.
Consistentfollowup
Thestudydesigniswellestablishedandfrequencyoffollow-upisdetailed.Wedeterminevisitseach6months.Thiscorrespondstoregularfollow-up.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page22of34
5.1.2 Communication
Communicationmust be adapted to language and comprehension impairment. As PLWDshavememory problems and fail to recollect things, persons or events, a brochure of thestudywill be given.During theproject, PLWDswill receive informationon the trial. If thePLWDisenrolled inthecontrolgroup,hecanstillexpecttoreceiveaccesstotheplatformonceparticipationintheclinicaltrialsends.
5.1.3 Engagement
An engagement experience is informative, constructive, and mutually beneficial. Mostimportantly,PLWDsandstakeholdersshouldthoroughlyvettheirengagementstrategiesatthe earliest possible stages. The Dialogue participants identified the following types ofquestionsthatbothresearchersandPLWDswillconsiderwhenevaluatingtheirengagementapproaches:
Table13:EngagementquestionnaireforPLWD
Q1 Whatarewetryingtoachieve?
A1 C-MMDwilldeterminespecificgoalsoftheengagementforPLWD
Q2 Whoarewetryingtoengage?
A2Explain who the target population or stakeholder group is and using thatassessmenttoinformselectionofwhombesttoengage
Q3 Whenshouldweengage?
A3 Identifyingwhatpointsalongagivenprocessareoptimalforeachengagement
Q4 Howshouldweengage?
A4 Selectingthemethodsmostsuitableforeachengagement
Q5 Whatistheexpectedimpact?
A5Developingoridentifyingmetrics(outcomesorendpoints)thatcanbeassessedtodeterminewhetheranengagementachievedtheoriginalgoals
Q6 Whatwastheactualimpact?
A6Implementing frequent checkpoints during and following the engagements toencouragecommunication,collectdataontheoutcomes/endpoints,andpromptlyaddressanyissues
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page23of34
Furthermore, such consideration will offer a greater likelihood that an engagement orengagementstrategywillachievemaximumimpactandlikelybeconsideredmeaningfulbybothpatientsandstakeholders.
5.1.4 BuildconfidenceandtrustforPLWDs
To engage patients effectively and build their confidence, we will focus on the followingkeys:credibility,literacy,expectationmanagement,accessibilityrelatedtopeople.
5.1.4.1 Credibility
Wewillbuildcredibility,andspeaktopatientsinatrustedvoice.Theindustryhasseengreatresults when recruitmentmaterials include testimonials from patients or caregivers, whohave participated in focus groups or trials. In addition to testimonials, there are severalotherwaystobuildcredibility:
1. Takingempathyintoaccount2. Creatingandprovidingtoolsthatgiveafeelingofbeingastakeholderinthedisease
care3. CreatingandprovidingtoolstomakeiteasyforaPLWD’scircleofcaretobemore
involved in their loved ones journey, can further expand a sense of empathy andengagement.
5.1.4.2 Literacy
AccordingtotheDepartmentofHealth&HumanServices,only12%ofU.S.adultspossessproficient health literacy. One approach that is effective in addressing the challenge ofhealth literacy is creating interactive infographics of trial protocols. These infographicsprovideasimplevisualdepictionofoftencomplicatedschedulesthatmaketheinformationeasier tounderstand. These infographics arenotonlyuseful for patients, but also for sitestaffandinvestigators.
5.1.4.3 ExpectationManagement
FAQresponsesarewrittenandpresentedbynursesorotherpatients.
5.1.4.4 Accessibility
Clinicaltrialmaterialsareappropriatetoage,disease,sensory impairment.Thismaterial isshareableandsupportedbymultipledevices.
5.1.4.5 Reliability
CMMD-Prowillprovide informationthataresensitivetoculturalandgendernuances,andwillavoidimageryanddesignapproachesthatareoutoftouchwiththepatientpopulation.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page24of34
5.2 Strategyforcaregiver
5.2.1 Improvingconsent
For many caregivers, obtaining informed consent can be a barrier. In order to improveenrolmentinthestudy,inclusionandexclusioncriteriaarelargeinthisstudy.
Oneofthedifficultiesisrepresentedbythefactthatthecaregiversarecriticalpartnersandsupport assistance in the consent process. The burnout due to the caregiving may be areasontodeclineparticipation.
Toimproveenrolmentinthestudy,caregiversaremorelikelytoparticipateif:
Table14:KeyfactorstoimproveenrolmentforCaregivers
Keyfactors Description
Clearcommunication
§ Caregiversreceiveclearinformationaboutthetrial.Thisinformationmustbeadaptedtotheroleofthecaregiverinthestudyandtothelevelofdisease(abrochurewithquestionsandanswers–FAQ-couldbegiventocaregivers)
§ ExpectedoutcomesforcaregiversandPLWDofthetrialarediscussed,
§ DirectindividualbenefitsoftheuseoftheCAREGIVERSPRO-MMDplatformarediscussedwithcaregivers.Directreturnoninvestmentisclearlyexplainedwithcaregivers.
§ Theyareclearlyinformedofethicalproceduresanddataprotection§ Adverseeventsarescarcecomparedtoadrugtrial.Theyare
explainedtothecaregiver.
Consistentfollowup
Thestudydesigniswellestablishedandfrequencyoffollow-upisdetailed.Wedeterminevisitseach6months.Thisfrequencycorrespondstotheregularfollow-up.
5.2.2 Communication
Caregiversmaybesurprisedtolearnthatenrolmentoftheirlovedoneintoaclinicaltrialalsomeansarealcommitmentontheirpart.
Ifthecaregiverisenrolledinthecontrolgroup,hecanstillexpecttoreceiveaccesstheplatformonceparticipationintheclinicaltrialsends.
5.2.3 EngagementTable15:EngagementquestionnaireforCaregivers
Q1 Whatarewetryingtoachieve?
A1 C-MMDwilldeterminespecificgoalsoftheengagementforPLWDandcaregiver
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page25of34
Q2 Whoarewetryingtoengage?
A2Explain who the target population or stakeholder group is and using thatassessmenttoinformselectionofwhombesttoengage
Q3 Whenshouldweengage?
A3 Identifyingwhatpointsalongagivenprocessareoptimalforeachengagement
Q4 Howshouldweengage?
A4 Selectingthemethodsmostsuitableforeachengagement
Q5 Whatistheexpectedimpact?
A5Developingoridentifyingmetrics(outcomesorendpoints)thatcanbeassessedtodeterminewhetheranengagementachievedtheoriginalgoals
Q6 Whatwastheactualimpact?
A6Implementing frequent checkpoints during and following the engagements toencouragecommunication,collectdataontheoutcomes/endpoints,andpromptlyaddressanyissues
Furthermore, such consideration will offer a greater likelihood that an engagement orengagementstrategywillachievemaximumimpactandlikelybeconsideredmeaningfulbybothpatientsandstakeholders.
5.2.4 Buildconfidenceandtrustforcaregivers
To engage patients effectively and build their confidence, we will focus on the followingkeys:credibility,literacy,expectationmanagement,accessibilityandthatrelatestopeople.
5.2.4.1 Credibility
TheC-MMDteamwillbuildcredibility,andspeaktopatientsinatrustedvoice.Theindustryhas seen great results when recruitment materials include testimonials from patients orcaregivers, who have participated in a trial. In addition to testimonials, there are severalotherwaystobuildcredibility:
1- Takingempathyintoaccount2- Creatingandprovidingtoolstomakeiteasyforacaregiver’scircleofcaretobe
more involved and give a feeling of stakeholder in the care,that can furtherexpandasenseofempathyandengagement.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page26of34
5.2.4.2 Healthliteracy
AccordingtotheDepartmentofHealth&HumanServices,only12%ofU.S.adultspossessproficient health literacy. One approach that is effective in addressing the challenge ofhealth literacy is creating interactive infographics of trial protocols. These infographicsprovideasimplevisualdepictionofoftencomplicatedschedulesthatmaketheinformationeasier tounderstand. These infographics arenotonlyuseful for patients, but also for sitestaffandinvestigators.
5.2.4.3 ExpectationManagement
FAQresponsesarewrittenandpresentedbyhealthprofessionals.
5.2.4.4 Accessibility
Clinicaltrialmaterialsareageappropriate,shareableandsupportedbymultipledevices.
5.2.4.5 Reliability
C-MMDwill provide information that is sensitive to cultural and gendernuances, andwillavoidimageryanddesignapproachesthatareoutoftouchwiththepatientpopulation.
5.3 Strategyformedicaldoctors
Dependingontheroleofeachprofessional,differentstrategieswillbeadopted:
1- Screeningofthetotalactivefileofpatientswithneurocognitiveimpairmentwhoarefollowedbypsychologistsorspecialistsinvolvedinthepilotstudy.Professionalswillscreen:
o Inmemoryclinicso Inhospitaldaycareo Inhospitalization(rehabilitation,acutecare,etc.)
Ifpatientsmeettheinclusionandexclusioncriteria,theteamwillidentifyifthepatientandthecaregiveraccepttoparticipateinthestudy.
2- Informationwillbesenttohealthpartnersincloseproximitytothepilotstudy(medicaldoctors,psychologists,nurses,etc.).Thesehealthpartnerswillscreentheiractivefilesofpatientswithneurocognitivedisorders:
o Inmemoryclinicso Inhospitalo Inhospitaldaycareordaycarecentreso Inthecommunity
IfaPLWDandhiscaregivermeettheinclusioncriteria,thehealthprofessionalwillproposetothedyadtoparticipatenthestudy.Thisprofessionalwillcontacttheteaminvolvedinthestudy.Thecriteriawillbechecked.Ifthecriteriaareverified,anappointmentforthedyadwillbebookedwiththepilotteam.
3- Information will be sent to other health professionals (general practitioners,neurologists, psychiatrists, geriatricians, nurses, psychologists, etc.) in order to
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page27of34
promoteawarenessofthestudy.Theywillreceiveanddisseminateinformationonthe trial (flyers, newsletter articles, information on web sites, public serviceannouncements,pressreleases,etc.)
Ateachstage,theroleofthepilothealthteamis:
- Toscreenactivefilesofpatientswithneurocognitiveimpairment- Tobeactivelyinvolvedinremindingnearbyhealthandsocialprofessionalsin
ordertoachieveinclusionintime.- Toverifytheinclusionandexclusioncriteria- TogiveclearinformationontheCMMD-ProPlatformandthestudyprotocol- Todiscussoutcomes,benefits/risks,roleandresponsibilitiesofeachpartner;- Toverifythewillingnesstocompletethestudy- Todescribethetimetableofthestudy- ToverifytheabilitytouseICT- Toobtaininformedconsent- Tofollowcompletionofthestudyanddealwithissues(dyadsthatdonotuse
theplatform,dyadswhichwanttowithdrawinformedconsent,etc.)
5.4 StrategyforsocialprofessionalsInneurocognitivedisorders,theroleofsocialworkersisimportant;theyoftenhavecloselinkswithmedicalteamsanddyads.Inthepilotstudy,theymayplaydifferentrolesforparticipationandcompletionofthestudy.
Theroleofsocialworkersmaybe:
1. screeningthetotalactivefileofpatientswithneurocognitiveimpairmentwhoarefollowedo Bysocialworkersinthecommunityo Inhospitalization(rehabilitation,acutecare,etc.)o Inmemoryclinicsordaycarecentres
2. givinginformationinordertopromotetheawarenessofthestudy.Theywillreceiveanddisseminateinformationonthetrial(flyers,newsletterarticles,informationonwebsites,publicserviceannouncements,pressreleases,etc.)
Ifpatientsmeettheinclusionandexclusioncriteria,theteamwillidentifyifthepatienthasacaregiverwhoacceptstoparticipateinthestudy.
Theroleofsocialworkeristomotivatethedyadtoparticipateandcompletethestudy.
IfaPLWDandhiscaregivermeettheinclusioncriteria,thehealthprofessionalwillproposetothedyadparticipationinthestudy.Thisprofessionalwillcontacttheteaminvolvedinthestudy.Thecriteriawillbechecked.Ifthecriteriaareverified,anappointmentforthedyadwillbebookedwiththepilotteam.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page28of34
Itisessentialthatthepilotteamhascloselinkswithsocialworkers.Therewillbecommunicationbetweenprofessionalsanddyadsthroughoutthestudy.Thisisessentialinthefollow-up.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page29of34
6 StrategyforRetentionThefirststepistofindthe«high-risk»dyadsinthestudy:strategiesusefultoinvestigatorswishingtoretainthese“high-risk”dyadsinthestudyprotocolinclude:screeningpatientsfordrop-outriskpriortorandomizationandtrackingthemcloselythroughoutthestudy.
The RAQ 7 item-scale (Research Attitude Questionnaire) (Rubright) is used to assess thewillingness of patients to participate and complete a study. This scale is not validated fortestinganICTdeviceindementiaandnocut-offisdefined.Thisscalemaybeausefultooltohelppilotteamstoselectdyadswhenadoubtispresent.
6.1 Categorizingparticipants
Initial randomization screening of participants on both demographic and psychologicalvariables (e.g. caregiver employment and educational status, caregiver depression, PLWDquality of life, etc.)may help identify those at greatest risk for studywithdrawal or poorstudy protocol adherence, permitting the C-MMD clinical team to develop retentionstrategiesaimedatthishigh-riskgroup.
Categorizing participants into separate groups based on completion status (on-timecompletersv.thosewitherraticstudyattendance)isausefuldataanalyticstrategy.
6.2 Possibleriskmitigationstrategies
Measuretominimizeparticipantburdenanddrop-out:
Table16:Retentionriskmitigationstrategies
Measure
Flexibleappointmentscheduling For“high-risk”dyads,proposeflexibleagenda.
Providingincentives
PeoplecankeeptabletprovidedbytheConsortiumoncestudyisdone.Forthecontrolgroupdyad:ifthedyadisenrolledinthecontrolgroup,itcanstillexpecttoreceiveplatformaccessonceparticipationintheclinicaltrialsends.
Socialsupport High-riskdyadswillbenefitfromsocialsupport
Contactbetweenappointments
High-riskdyadswillbecontactedbetweenappointments
Ifadyaddoesnotusetheplatformduringonemonth,aphonecontactwillbemadeinordertosolvethisissue
Createremindersforappointments
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page30of34
Provideadetailedorientationsession Improvedcommunicationforhigh-riskdyads.
Provideuser-friendlyplatformIntegratepersonalisedsoftware
Gamificationstrategiestomotivateend-usertousetheplatform
ProvidecontentsProvidingusefulcontents,personalisedtocaregiversandPLWDisnecessarytominimizedrop-out
It is likely that the same factors predict patient clinic attendance and adherencewith themedical regimen. Consequently, identification of these risk factors as part of routine caremayhelp theC-MMDclinical teambetteraddress theparticular challenges facedbyhigh-riskdyads.
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page31of34
7 ANNEXES7.1 Annex1:DSM-IVCriteriaAPA1994
A. Developmentofmultiplecognitivedefectsexpressedthrough:a. Memoryimpairmentb. Impairmentinoneormoreofthefollowingcognitivedomain
i. Aphasiaii. Apraxia(impairedabilitytocarryoutmotoractivitiesdespiteintact
motorfunction)iii. Agnosia(failuretorecognizeoridentifyobjectsiv. Executivefunctioning(planning,organization,abstraction…)
B. Cognitivedeficitscausesignificantimpairmentindailyfunction(social,occupational)andimplyasignificantdeclinefrompreviousleveloffunctioning.
C. ThecourseischaracterizedbygradualonsetandcontinuingcognitivedeclineD. Cognitivedefectsarenotdueto
a. Other central nervous system conditions that cause progressive deficits inmemoryandcognition
b. Systemicconditionsknowntocausedementiac. Substance-inducedconditions
E. DeficitsdonotoccurexclusivelyduringcourseofdeliriumF. Disturbance not better accounted for by another Axis I disorder (eg major
depressivedisorder,schizophrenia)
7.2 Annex2:MCI-Albert-Petersen2011
A- Complaintsconcerningachangeincognitionincomparisonwithpreviouslevel.Thiscomplaintcanbeobtainfromthepatient,theirfamilyorfromaskilledclinician
B- Impairment inoneormorecognitivedomain-Scoresarebelow1 to1.5 standarddeviation below the mean for their age and educational level. If repeatedevaluationsareavailable,adeclineinperformanceshouldbeevidentovertime.
C- Preservation of independence in functional abilities despite mild problems withcomplextasks(payingbills,cooking…)
D- Notdemented:Nosignificantimpairmentinsocialandoccupationalfunctioning
7.3 Annex3:ResearchAttitudeQuestionnaire-7item
• Ihaveapositiveviewaboutmedicalresearchingeneral• Medicalresearcherscanbetrustedtoprotecttheinterestsofpeoplewhotake
partintheirstudies
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page32of34
• Wehavesomeresponsibilitytohelpothersbyvolunteeringformedicalresearch• Societyneedstodevotemoreresourcestomedicalresearch• Participatinginmedicalresearchisgenerallysafe• IfIvolunteerformedicalresearch,Iknowmypersonalinformationwillbekept
privateandconfidential• Medicalresearchwillfindcuresformajordiseaseduringmylifetime
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page33of34
8 References1. MarilynS.Albert,StevenT.DeKosky,DennisDickson,BrunoDubois,HowardH.
Feldman,NickC.Fox,AnthonyGamst,DavidM.Holtzman,WilliamJ.Jagust,RonaldC.Petersen,PeterJ.Snyder,MariaC.Carrillo,BillThies,andCreightonH.Phelps.ThediagnosisofmildcognitiveimpairmentduetoAlzheimer’sdisease:RecommendationsfromtheNationalInstituteonAging-Alzheimer’sAssociationworkgroupsondiagnosticguidelinesforAlzheimer’sdisease.AlzheimersDement2011May7(3):270-279
2. AmericanPsychiatricAssociation.DiagnosticandStatisticalManualofMentalDisorders,4thedition.Washington,D.C.:AmericanPsychiatricPress,1994.
3. FolsteinMF, Folstein SE,McHugh PR. "Mini-mental state": a practicalmethod forgradingthecognitivestateofpatientsfortheclinician.JPsychiatrRes.1975;12:189-198.
4. RubrightJ,CaryM,KarlawishJ,KimS.Measuringhowpeopleviewbiomedicalresearch:reliabilityandvalidityanalysisoftheresearchattitudesquestionnaire.JEmpirResHumResEthics2011;6(1):63-68
5. GrillJD,K.J.AddressingthechallengestosuccessfulrecruitmentandretentionAlzheimer'sdiseaseclinicaltrials.AlzheimersResTher,2010;2(6),34.
6. CaryM,RubrightD,GrillJ,KarlawishJ.WhyarespousalcaregiversmoreprevalentthannonspousalcaregiversasstudypartnersinADdementiaclinicaltrials?AlzheimerDisAssocDisord2015;29(1):70-74.
7. AFA,AssociationFrançaisedesAidants.Lesprochesaidants:unequestionsociétale.Accompagnerpourpréserverlasanté[Internet].2016.Link:https://www.isere.fr/mda38/aider-aidants/Documents/Proches%20aidants.pdf
8. SpadinP,VaccaroCM.Lavitariposta:icostisocialiedeconomicidellamalattiadiAlzheimer[Internet].FrancoAngeli;2007.Link:http://www.alzheimer-aima.it/img/costieconomici_sintesi.pdf
9. RiveraJ,BermejoF,FrancoM,Morales-GonzálezJM,Benito-LeónJ.UnderstandingcareofpeoplewithdementiainSpain:Cohabitationarrangements,rotationandrejectiontolongtermcareinstitution.InternationalJournalofGeriatricPsychiatry.February2009;24(2):142-8.Link:http://onlinelibrary.wiley.com/doi/10.1002/gps.2081/full
10. EspañaD.Cuidadorasycuidadores:elefectodelgéneroenelcuidadonoprofesionaldelosmayores.2008;Link:
D4.4TargetGroupDefinition
CAREGIVERSPRO-MMD
Page34of34
http://www.imserso.es/interpresent3/groups/imserso/documents/binario/boletinopm35.pdf
11. GrillJD,RamanR,ErnstromKetal.EffectofstudypartnerontheconductofAlzheimerdiseaseclinicaltrial.Neurology2013;80:282-288.
12. DodgeH,KatsumataY,ZhuJ,MattekN,BowmanM,GregoM,WildK,KayeJ.Characteristicsassociatedwithwillingnesstoparticipateinarandomizedcontrolledbehavioralclinicaltrialusinghome-basedpersonalcomputersandawebcam.Trials2014;15:508
13. JacovaC,HsiungG-YR,FeldmanHH.Dropoutsandrefusalsinobservationalstudies:lessonsforpreventiontrials.Neurology.November2006;67(9Suppl3):S17-20.Link:http://www.ncbi.nlm.nih.gov/pubmed/17101929
14. SmithGS.HandbookofDepressioninAlzheimer’sDisease.IOSPress2015.Link:http://www.iospress.nl/book/handbook-of-depression-in-alzheimers-disease/
15. VanMierloLD,MeilandFJM,VandeVenPM,VanHoutHPJ,DröesR-M.EvaluationofDEM-DISC,customizede-adviceonhealthandsocialsupportservicesforinformalcarersandcasemanagersofpeoplewithdementia;aclusterrandomizedtrial.IntPsychogeriatr.agostode2015;27(8):1365-78.Link:http://www.ncbi.nlm.nih.gov/pubmed/25872457
16. BlomMM,ZaritSH,GrootZwaaftinkRBM,CuijpersP,PotAM.EffectivenessofanInternetinterventionforfamilycaregiversofpeoplewithdementia:resultsofarandomizedcontrolledtrial.PLoSONE.2015;10(2):e0116622.Link:http://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-17
17. Cristancho-LacroixV,WrobelJ,Cantegreil-KallznI,DubT,RouquetteA,RigaudAS.Aweb-BasedpsychoeducationalprogramforinformalcaregiversofpatientswithAlzheimer’sdisease:apilotrandomizedcontrolledtrial.JMedInternetRes.2015May;17(5):e117
18. Cristancho-LacroixV,MoulinF,WrobelJ,BatrancourtB,PlichartM,DeRotrouJ,Cantegreil-KallznI,A,RigaudAS.Aweb-BasedlprogramforinformalcaregiversofpatientswithAlzheimer’sdisease:aniterativeuser-centereddesign.JMIRResProtoc.2014Jul-Sep;(3):e46.